Display options
Cite
Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015;6(4):160-9doi: 10.1177/2040622315582353.
Peters, J., Booth, A., & Peters, R. (2015). Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Therapeutic advances in chronic disease, 6(4), 160-9. https://doi.org/10.1177/2040622315582353
Peters, Jean, et al. "Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review." Therapeutic advances in chronic disease vol. 6,4 (2015): 160-9. doi: https://doi.org/10.1177/2040622315582353
Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015 Jul;6(4):160-9. doi: 10.1177/2040622315582353. PMID: 26137206; PMCID: PMC4480546.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Chronic Dis. 2015 Jul;6(4):160-9. doi: 10.1177/2040622315582353.

Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review.

Therapeutic advances in chronic disease

Jean Peters, Andrew Booth, Ruth Peters

Affiliations

  1. School of Health and Related Research (ScHARR). The University of Sheffield, Regent Court, Sheffield S1 4DA, UK.
  2. School of Public Health, Imperial College London, St Mary's Campus, London W2 1PG, UK.

PMID: 26137206 PMCID: PMC4480546 DOI: 10.1177/2040622315582353

Abstract

BACKGROUND: There is some evidence to suggest a possible association between calcium channel blocker (CCB) use and a lower decline in cognitive function compared with use of other hypertensive treatments. In particular, there is an emerging interest in the potential for specific CCBs, particularly the dihydropyridine CCBs nitrendipine, nicardipine, cilnidipine, lercandipine, nimodipine, azelnidipine and nilvadipine. The aim of this review was to assess the evidence relating to these specific CCBs and incident cognitive decline or dementia in humans.

METHODS: A systematic review of the literature was carried out. The databases MEDLINE, Embase and PsychINFO were searched from 1980 to 18 April 2014. All abstracts were reviewed by two independent reviewers.

RESULTS: From 753 unique records, 16 full text articles were examined and three retained. The three articles reported data from two studies. A 12-week double-blind randomized controlled trial of nitrendipine compared with cilazapril and a longer and larger double-blind placebo-controlled trial also of nitrendipine, namely the Systolic Hypertension in Europe trial (SYST-EUR). Nitrendipine was associated with a reduction in incident dementia in the SYST-EUR trial. There was no association seen for cognitive outcomes in the smaller trial.

CONCLUSION: At present there is limited evidence to suggest that nitrendipine may be associated with reduction in incident dementia. This association comes from a single trial and needs to be replicated. Furthermore, there is no high-quality evidence for any of the other potential candidate CCBs.

Keywords: calcium antagonists; calcium channel blockers; cognitive decline; dementia; hypertension

References

  1. Arch Intern Med. 2002 Oct 14;162(18):2046-52 - PubMed
  2. Ann Intern Med. 1992 Apr 15;116(8):615-23 - PubMed
  3. Neurobiol Aging. 2005 Feb;26(2):157-63 - PubMed
  4. Int J Clin Pract. 2011 Dec;65(12):1295-305 - PubMed
  5. Br J Pharmacol. 2013 Jul;169(6):1203-10 - PubMed
  6. Eur J Pharmacol. 2011 Jun 1;659(2-3):124-9 - PubMed
  7. CMAJ. 1999 Sep 7;161(5):501-6 - PubMed
  8. J Alzheimers Dis. 2010;20(3):903-14 - PubMed
  9. Heart Dis. 2002 Nov-Dec;4(6):380-6 - PubMed
  10. Cochrane Database Syst Rev. 2002;(3):CD000147 - PubMed
  11. J Hypertens. 2014 Oct;32(10):1945-57; discussion 1957-8 - PubMed
  12. Am J Geriatr Pharmacother. 2009 Oct;7(5):250-61 - PubMed
  13. Stroke. 2005 Jun;36(6):1218-26 - PubMed
  14. Arch Neurol. 2006 May;63(5):686-92 - PubMed
  15. J Cardiovasc Pharmacol. 1994;24 Suppl 3:S73-7 - PubMed
  16. Neurobiol Aging. 2008 Feb;29(2):306-8 - PubMed
  17. Alzheimer Dis Assoc Disord. 1991;5 Suppl 1:S7-12 - PubMed
  18. Vasc Health Risk Manag. 2006;2(4):491-8 - PubMed
  19. Fundam Clin Pharmacol. 2002 Dec;16(6):527-35 - PubMed
  20. Expert Rev Neurother. 2009 Sep;9(9):1413-31 - PubMed
  21. Lancet. 1998 Oct 24;352(9137):1347-51 - PubMed
  22. Am J Epidemiol. 2005 Feb 1;161(3):280-8 - PubMed
  23. Mol Med. 2011 Mar-Apr;17(3-4):149-62 - PubMed

Publication Types

Grant support